ENDOLOGIX INC's ticker is and the CUSIP is 29266SAB2. A total of 8 filers reported holding ENDOLOGIX INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $38,243,000 | +9.6% | 40,500,000 | 0.0% | 1.34% | +11.1% |
| Q1 2018 | $34,899,000 | -3.4% | 40,500,000 | 0.0% | 1.21% | -14.9% |
| Q4 2017 | $36,112,000 | +3.1% | 40,500,000 | 0.0% | 1.42% | -9.9% |
| Q3 2017 | $35,030,000 | +2.1% | 40,500,000 | 0.0% | 1.58% | -13.8% |
| Q2 2017 | $34,309,000 | -14.3% | 40,500,000 | 0.0% | 1.83% | +18.6% |
| Q1 2017 | $40,013,000 | +13.0% | 40,500,000 | 0.0% | 1.54% | +5.8% |
| Q4 2016 | $35,425,000 | -8.3% | 40,500,000 | +1.2% | 1.46% | -11.4% |
| Q1 2016 | $38,632,000 | +18.7% | 40,000,000 | +33.3% | 1.64% | +24.7% |
| Q4 2015 | $32,548,000 | – | 30,000,000 | – | 1.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Context Capital Management, LLC | 4,150,000 | $3,537,000 | 2.57% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 40,500,000 | $34,899,000 | 1.21% |
| PFM Health Sciences, LP | 47,642,000 | $41,210,000 | 0.84% |
| Partner Investment Management, L.P. | 450,000 | $389,000 | 0.42% |
| SSI INVESTMENT MANAGEMENT LLC | 2,000,000 | $1,719,000 | 0.14% |
| LINDEN ADVISORS LP | 2,928,000 | $2,536,000 | 0.06% |
| AMUNDI ASSET MANAGEMENT US, INC. | 8,250,000 | $7,095,000 | 0.01% |
| Citadel Advisors | 18,560,000 | $15,955,000 | 0.01% |
| WOLVERINE ASSET MANAGEMENT LLC | 125,000 | $106,000 | 0.00% |